Annual Report and Shareholder Meeting
Te ripoata me te hui a tau ma nga kaipupuri hea
Revenue increased to $1.90m (up from $0.32m in FY24) with strong momentum expected to continue into FY26.
We have released our Annual Report for the 12 months ended 30 June 2025 (FY25). It is available on Rua’s website: www.ruabio.com/annual-report.
Kua tuku atu i nga korero mo te kamupene o Rua mo te tau kua taha ake nei. Nga piki me nga heke. I te mutunga iho, he marakerake te kite atu i nga mahi whai hua e whaia nei matou.
The Annual Report provides an overview of Rua’s year, focused on the execution of its highly scalable strategy, anchored in genetics and distribution, which is now translating into tangible commercial results.
Rua’s financial performance was previously highlighted with the release of our unaudited financial statements on 1 September 2025. Rua reported a marked increase in revenue and a significantly reduced loss before tax of $3.46m (FY25: $13.72m). Revenue rose to $1.90m (FY24: $0.32m), with revenue from customers reaching $1.51m (FY24: $86K).
It should be noted that although Rua have increased revenue and received $1.5m from shareholders during the financial year, forecasts for the next 12 months indicate that the Group will not have sufficient cash to meet its minimum expenditure commitments and support its current levels of activity without undertaking additional action. For further information and context please refer to the Going Concern Disclosure (Note 2(f) in the Financial Statements).
The Directors continue to believe Rua is well positioned for growth, supported by shareholder backing and expanding sales pipelines in key global markets.
Subsequent operational and Financial Update
Rua has entered FY26 with strong momentum, underpinned by continued shareholder support and record sales across multiple markets.
Following the balance date of 30 June 2025, the company secured a further $1.26m through a combination of equity and debt, primarily used to purchase inventory to accelerate growth in key markets.
Operational highlights since 30 June 2025 include:
Australia: Record monthly sales as a result of expanding portfolio and key clinic relationships.
New Zealand: Record monthly sales were achieved in July in line with new product launches.
Germany: Launch of Rua’s first New Zealand grown product, leveraging legacy genetics and delivering on the strategy to take New Zealand genetics to key export markets.
United Kingdom: Growing sales in this early-stage market, with increasing engagement with key clinics and prescribers.
Czechia: Market entry achieved with the first product launched, securing valuable first-mover advantage and a pipeline for expansion.
Further capital requirements
To support its ongoing growth, Rua will require additional capital to support growing sales demand. The Board is working with its key shareholders and advisors on further capital raise options.
“Rua has achieved significant commercial milestones and is now generating revenue in five key markets”, said Paul Nake, Chief Executive Officer. “We are extremely well placed to build on this momentum and further capital will provide the runway we need to accelerate growth and deliver on our strategy”.
Annual Shareholder Meeting
3.00pm Tuesday 28 October
The 2025 Annual Shareholder Meeting will be held virtually via Computershare’s online meeting platform at https://meetnow.global/nz
Each year, Rua Bioscience holds its Annual Shareholders Meeting (ASM), and we encourage as many participants as possible to join. The meeting is accessible online through the MeetNow platform.
What will be discussed?
The Agenda and details of the meeting is captured in the Notice of Meeting.
How to vote?
All the details on voting are capture in the Proxy Voting Form.
We urge all shareholders to review the Notice of Meeting thoroughly and participate actively in shaping the future of Rua Bioscience. Your voice matters.
Outlook
Rua is expecting sales momentum to continue throughout FY26 with revenue growth anticipated from both established and emerging markets.
The company remains focused on accelerating commercial performance, strengthening international partnerships and delivering on its highly scalable strategy. Alongside this, Rua will continue to uphold its kaupapa by delivering social impact in Tairawhiti and beyond.
“Rua’s waka is set on a clear course”, said Paul Naske, Chief Executive Officer. “We are confident in the opportunities ahead and committed to building long-term, sustainable value for our shareholders and our people”.
Kia tau iho nga manaakitanga ki runga i a tatou katoa.